18H Stock Overview
PreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
PreveCeutical Medical Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.011 |
| 52 Week High | CA$0.028 |
| 52 Week Low | CA$0.011 |
| Beta | 1.06 |
| 1 Month Change | -30.00% |
| 3 Month Change | -25.00% |
| 1 Year Change | -41.67% |
| 3 Year Change | 31.25% |
| 5 Year Change | -68.18% |
| Change since IPO | -88.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| 18H | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -30.0% | 1.5% | -0.5% |
| 1Y | -41.7% | -27.9% | 2.5% |
Return vs Industry: 18H underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: 18H underperformed the German Market which returned 1.8% over the past year.
Price Volatility
| 18H volatility | |
|---|---|
| 18H Average Weekly Movement | 10.3% |
| Pharmaceuticals Industry Average Movement | 7.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 18H's share price has been volatile over the past 3 months.
Volatility Over Time: 18H's weekly volatility has decreased from 23% to 10% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Stephen Van Deventer | www.preveceutical.com |
PreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. Its pipeline products include Cannabinoid Sol-Gel Delivery, a cannabinoid-based nose-to-brain delivery system that provides relief from various indications, including pain, inflammation, seizures, and neurological disorders; Non-Addictive Analgesic for pain management; BSV Peptide Program that targets cancer progression; and Dual Gene Therapy for type 2 diabetes and obesity. The company also develops a range of medicinal cannabis-based products.
PreveCeutical Medical Inc. Fundamentals Summary
| 18H fundamental statistics | |
|---|---|
| Market cap | €10.95m |
| Earnings (TTM) | -€352.73k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-31.0x
P/E RatioIs 18H overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 18H income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$517.52k |
| Earnings | -CA$517.52k |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.00097 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -70.0% |
How did 18H perform over the long term?
See historical performance and comparison